loading...| Preferred Name |
clofibrate |
|
| Synonyms |
Atromid-S |
|
| Definitions |
An aryloxyisobutyric acid derivate with antihyperlipidemic activity. Although the exact mechanism of action has not been fully characterized, clofibrate may enhance the conversion of very-low-density lipoprotein (VLDL) to low-density lipoprotein (LDL), decreasing the production of hepatic VLDL, inhibiting cholesterol production, and increasing fecal excretion of neutral sterols. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C378" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C378" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042108 |
|
| altLabel |
Atromid-S CFB ethyl 2-(4-chlorophenoxy)-2-methylpropanoate ethyl p-chlorophenoxyisobyturate 2-(4-chlorophenoxy)-2-methylpropanoic acid ethyl ester |
|
| CAS Registry |
637-07-0 |
|
| cui |
C0009002 C0591129 |
|
| definition |
An aryloxyisobutyric acid derivate with antihyperlipidemic activity. Although the exact mechanism of action has not been fully characterized, clofibrate may enhance the conversion of very-low-density lipoprotein (VLDL) to low-density lipoprotein (LDL), decreasing the production of hepatic VLDL, inhibiting cholesterol production, and increasing fecal excretion of neutral sterols. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C378" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C378" NCI Thesaurus) |
|
| Legacy PDQ ID |
5344 |
|
| LT |
TRD |
|
| NCI ID |
C378 |
|
| notation |
CDR0000042108 |
|
| NSC Code |
79389 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
clofibrate |
|
| tui |
T109 T121 |